益盛药业(002566) - 2022 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2022 was ¥428,409,146.26, a decrease of 5.82% compared to ¥454,884,074.49 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was ¥43,812,015.69, an increase of 5.90% from ¥41,371,047.86 year-on-year[25]. - The net cash flow from operating activities decreased by 39.79% to ¥72,426,598.89 from ¥120,294,568.26 in the previous year[25]. - The basic earnings per share increased to ¥0.1324, up 5.92% from ¥0.1250 in the same period last year[25]. - The company reported a decrease of 8.53% in net profit after deducting non-recurring gains and losses, totaling ¥32,817,432.17 compared to ¥35,876,286.87 in the previous year[25]. - The company's total revenue for the reporting period was ¥428,409,146.26, representing a decrease of 5.82% compared to the previous year[47]. - The pharmaceutical sector accounted for 82.01% of total revenue, with a year-on-year increase of 5.50% in this segment[48]. - The total profit for the first half of 2022 was CNY 87,892,527.35, compared to CNY 85,417,906.33 in the previous year, an increase of 2.9%[136]. - The company reported a net increase in cash and cash equivalents of ¥61,534,961.32 for the first half of 2022, contrasting with a decrease of ¥147,545,647.58 in the same period of 2021[142]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,888,592,843.66, reflecting a 0.85% increase from ¥2,864,366,655.13 at the end of the previous year[25]. - The company's total assets as of June 30, 2022, were CNY 2,974,259,795.98, an increase from CNY 2,935,747,364.14 at the beginning of the year[129]. - The total liabilities decreased to CNY 865,192,174.31 from CNY 898,658,750.33 at the start of the year[129]. - The inventory level was ¥1,586,034,217.18, accounting for 54.91% of total assets, showing a slight decrease from the previous year[54]. Research and Development - The company has developed 11 dosage forms and 117 varieties, with 49 products included in the National Basic Medical Insurance Drug List[38]. - The company holds 19 invention patents, 5 design patents, and 4 utility model patents, indicating a strong focus on innovation[45]. - Research and development expenses decreased by 36.99% to ¥13,327,785.79, primarily due to reduced clinical trial costs[47]. - The company has initiated research and development for new technologies aimed at enhancing product offerings[145]. - The company is focusing on enhancing its research and development capabilities to innovate new technologies and products[150]. Market and Business Strategy - The company is expanding its business model to include health foods and cosmetics, forming a complete ginseng industry chain[37]. - The company aims to leverage technological innovation and internal management to ensure sustainable development amidst a challenging market environment[33]. - The company plans to maintain its strategy of building a complete ginseng industry chain, increasing its ginseng reserves through self-cultivation and external procurement[64]. - Future guidance indicates a cautious outlook, with expectations of gradual recovery in revenue growth[145]. Social Responsibility and Governance - The company emphasizes social responsibility, focusing on environmental friendliness, resource conservation, and participation in social welfare activities[76]. - The company has implemented strict internal control systems to protect the rights of shareholders and creditors, ensuring timely disclosure of major information[77]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, including a specific emergency plan and regular employee training[75]. - The company has not received any administrative penalties for environmental issues during the reporting period[74]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 28,525[108]. - Zhang Yisheng holds 39.08% of the shares, totaling 129,348,530 shares[108]. - The total number of shares is 330,951,600, with 69.91% being unrestricted shares[106]. - There were no changes in the number of shares held by major shareholders during the reporting period[108]. Cash Flow and Financing - The total cash inflow from operating activities was ¥390,266,026.16, while cash outflow was ¥382,315,619.37, resulting in a positive net cash flow[140]. - The company received ¥170,000,000.00 from borrowings, while cash outflow for debt repayment was ¥170,000,000.00, leading to a net cash flow from financing activities of -¥7,331,676.21[142]. - The cash flow from financing activities showed a significant decrease in cash outflow for dividend distribution, which was ¥7,265,076.21 compared to ¥16,709,623.72 in the previous year[142]. Compliance and Accounting - The financial statements are prepared based on the going concern assumption and comply with the relevant accounting standards[159]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for at least 12 months from the reporting date[160]. - The financial report was approved by the board on August 25, 2022[158]. - The company adheres to the accounting policies and estimates as per the relevant accounting standards[161].